Humacyte, Inc.HUMA

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$0.57
Market cap
$158.0M
P/E
—
Revenue (TTM)
$2.1M
Net income
-$96.7M
Dividend yield
—
1-year total return
-64.7%
Net margin
-4560.8%
Revenue growth
159.3%
Debt / equity
1.16x

What Humacyte, Inc. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue————$0$2.0M
Net income-$66.5M-$26.5M-$12.0M-$110.8M-$148.7M-$40.8M
Free cash flow-$55.9M-$81.4M-$72.2M-$75.6M-$99.7M-$105.9M

More on HUMA.

Figures from Humacyte, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.